

AD \_\_\_\_\_

GRANT NUMBER DAMD17-96-1-6077

TITLE: Magnetic Resonance Spectroscopy: An Objective Modality  
to Identify the Pathology of Breast Neoplasms

PRINCIPAL INVESTIGATOR: Carolyn Mountford, Ph.D.

CONTRACTING ORGANIZATION: University of Sydney  
Sydney, NSW, Australia 2006

REPORT DATE: May 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are  
those of the author(s) and should not be construed as an official  
Department of the Army position, policy or decision unless so  
designated by other documentation.

19970711 110

DTIC QUALITY INSPECTED 2

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE May 1997	3. REPORT TYPE AND DATES COVERED Annual (29 Apr 96 - 28 Apr 97)	
4. TITLE AND SUBTITLE Magnetic Resonance Spectroscopy: An Objective Modality to Identify the Pathology of Breast Neoplasms			5. FUNDING NUMBERS DAMD17-96-1-6077	
6. AUTHOR(S)  Carolyn Mountford, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  University of Sydney Sidney, NSW, Australia 2006			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT  Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) <p>Fine needle aspirates have been obtained from patients undergoing breast surgery and analysed by proton MR spectroscopy at 8.5 Tesla and results compared with histopathological analysis. The results of the blinded MR analysis were compared with currently employed diagnostic approaches used in assessment of breast lesions. In the study so far discrimination between invasive carcinoma (n=82) and normal or benign (n=106) or carcinoma <i>in situ</i> (n=17) gave a sensitivity and specificity for benign versus invasive breast cancer of 95% and 96% respectively. The data are now being reanalysed by a robust multivariate analysis procedure.</p> <p>All carcinoma-<i>in-situ</i> samples with comedonecrosis or a microinvasive component (n=6) were ranked by MRS with invasive carcinoma while those with <i>in-situ</i> disease alone ranked with benign (n=11).</p>				
14. SUBJECT TERMS  Breast Cancer			15. NUMBER OF PAGES 48	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

\_\_\_\_ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

\_\_\_\_ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

\_\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

\_\_\_\_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
\_\_\_\_  
PI - Signature                      Date

## TABLE OF CONTENTS

	Page
<b>Introduction.....</b>	<b>3</b>
<b>Summary of Progress.....</b>	<b>3</b>
<b>Body .....</b>	<b>4</b>
<b>Purpose</b>	<b>4</b>
<b>Hypotheses</b>	<b>4</b>
<b>Expected Results</b>	<b>4</b>
<b>Research Plan and Progress to Date</b>	<b>5</b>
A. Sample Preparation	5
B. Correlation with Histological Criteria	5
C. Can MRS redefine the Precursor States of Breast Neoplasia?	7
D. Can MRS identify Chemical Profiles Associated with a Predisposition to Breast Cancer?	7
E. Longitudinal Study	8
<b>Methods</b>	<b>9</b>
Selection of Patients	9
The Participating Surgeons	9
The Royal Adelaide Hospital	9
Westmead Hospital	10
Concord Hospital	11
Magnetic Resonance Spectroscopy	11
Sample Handling	11
Data Collection	11
Pulse Sequence	11
Processing of MRS Data	12
Mathematical Analysis of MR Data from the UNIX	12
Histopathology	13
Expertise of the Pathologists	13
Rationale for the extent of Histological Assessment	13
Tissue Preparation	13
Quantification of Cell Types	13
Statistical Analysis	14
<b>Conclusions</b>	<b>15</b>
<b>References.....</b>	<b>16</b>
<b>Appendix I.....</b>	<b>20</b>
Acronym /Symbol Definition	
<b>Appendix II.....</b>	<b>Attached</b>
Manuscript accepted for publication in Radiology	

## INTRODUCTION

Recent improvement in breast cancer patient outcome is due to early diagnosis and effective management. The triage of mammography, clinical examination and fine needle aspiration biopsy is currently used to identify early breast cancers. Magnetic resonance imaging (MRI) has now been added to select women with breast abnormalities requiring biopsy. However, mammography and MRI are unable to distinguish cellular changes which correlate with the development of cancer and are unable to predict patient outcome. Fine needle aspiration cytology following mammography has reduced the incidence of unnecessary surgery but cannot predict at-risk status or tumour progression.

A new technology which could report on alterations to cellular chemistry and provide an adjunct to cytology would offer both independent and objective assessment of breast tissue. The potential then exists to identify an immediate or more distant predisposition towards breast cancer and thus screen, monitor and offer management protocols aimed at reducing tumour risk. Magnetic resonance spectroscopy offers this diagnostic modality and has been successfully developed to monitor tumour development and progression in other organs.

In the clinical situation where an established diagnosis of breast cancer has already been made, current predictors of patient outcome are of limited value. Despite methods of evaluation such as tumour typing and grading, surgico-histopathological staging, hormone and growth factor receptor status, genetic markers and ploidy, the reason for the variable clinical outcome in patients with established widespread metastatic disease remains unknown. The identification of biochemical markers both within primary and metastatic tumour deposits may be of great value in identifying patients who are likely to respond to specific therapeutic regimes.

**This proposal aims at developing magnetic resonance spectroscopy to be used as an adjunct to diagnostic histopathology. The MRS method offers the possibility of earlier diagnosis of cellular abnormalities in predisposed women, a precise documentation of the biological abnormalities of the cells, conclusive predictive value, clear distinction between cellular atypia, progressive and non-progressive carcinoma *in situ* and invasive cancer and the potential to determine patient outcome. These advantages over current technology warrant the thorough investigation of the application of magnetic resonance spectroscopy to breast pathology.**

## SUMMARY OF PROGRESS

To date 218 FNA have been obtained from patients undergoing breast surgery and analysed by proton MR spectroscopy at 360 MHz (8.5 Tesla) and results compared with histopathological analysis. The results of blinded MR analysis were compared with currently employed diagnostic approaches used in assessment of breast lesions. Invasive carcinoma was identified spectroscopically by an increased signal at 3.25 parts per million (ppm) attributable to choline-containing metabolites. Discrimination between invasive carcinoma (n=82) and normal or benign (n=106) or carcinoma *in situ* (n=17) was made based on the intensity of the 3.25 ppm resonance standardised to the resonance intensity at 3.05 ppm ( $p < 0.0001$ , Mann-Whitney U test). An MRS ratio of  $< 1.7$  was recorded for 102 out of 106 normal or benign lesions. All carcinoma-*in-situ* samples with comedonecrosis or a microinvasive component (n=6) were ranked by MRS with invasive carcinoma while those with *in-situ* disease alone ranked with benign (n=11). The sensitivity and specificity of MRS on FNB for benign versus invasive breast cancer was 95% and 96% respectively.

## BODY

### PURPOSE

1. To assess the sensitivity and specificity of  $^1\text{H}$  MRS (*ex vivo*) in the detection of neoplasia in breast, based on altered cellular chemistry.
2. Correlate alterations to MRS detectable cellular chemistry associated with breast tumour development and progression with established clinicopathological criteria.
3. Ascertain MRS markers which correlate with known clinical, epidemiological and genetic risk factors to be used to identify women at-risk of developing breast cancer.

### HYPOTHESES

Proton magnetic resonance spectroscopy can:-

1. Identify altered cellular chemistry in breast tissue independent of method of biopsy eg. open biopsy or fine needle biopsy.
2. Distinguish invasive cancer from normal breast tissue.
3. Distinguish between breast cancers of different type (e.g. lobular or ductal) and grade.
4. Distinguish between progressive and non progressive 'carcinoma *in situ*'.
5. Distinguish between 'normal' breast tissue and 'normal' breast tissue from women with differing risk factors for breast cancer (including age, pre- and post menopausal status, cyclic hormonal effects, genetic predisposition and family history).
6. Identify MRS markers of potential for malignancy in morphologically normal tissue from high risk patients.
7. Independent of histopathology, predict tumour behaviour and clinical outcome (e.g. response to therapy, patterns of metastases) and thereby be a significant predictor of patient survival.

### EXPECTED RESULTS

- Expertise in optimal handling and methodological protocols for assessment of breast tissue. **(Completed)**
- An MRS data bank on a full spectrum of breast tissue from normal (i.e. benign) to high grade malignancy. This will allow discrimination of new subsets of cancer-bearing patients for streaming into different management regimes with attendant improved psychosocial, cost efficiency and clinical outcomes. **(Underway)**
- Identification of new cellular chemistry parameters of tumour development in the breast. **(Underway)**
- Definition of MRS markers which correlate with a predisposition for breast cancer development. **(Underway)**
- Statistical verification of MR diagnostic criteria. **(Underway)**

## RESEARCH PLAN AND PROGRESS TO-DATE

### A. SAMPLE PREPARATION

#### Objective 1.

Optimise specimen handling and MR data acquisition protocols.

*Rationale:* Breast tissue contains substantial levels of fat which mask the diagnostic markers of tumour development and progression. Removal of as much of this fat component as possible from the biopsy prior to MRS analysis is both achievable and necessary.

**Results:** MRS handling criteria are established and global specimen handling protocols determined to ensure adequate histological correlation of MRS data on the test samples (see appendix II).

#### Objective 2.

Ascertain if the same MR criteria can be obtained on fine needle biopsy or aspirate.

*Rationale:* If the same MR information can be obtained from a fine needle aspirate or needle core biopsy, open surgery may not be a prerequisite for determining the diagnostic parameters.

**Results:** A previous study of MRS analysis on FNB of thyroid had established that as few as  $10^6$  cells were required to obtain one-dimensional MR spectroscopic data with adequate signal-to-noise in less than 15 minutes (256 accumulations) (39). To achieve an adequate breast sample, FNB was performed using multiple (typically 6) aspirated passes (23 gauge needle) either through the resected lesion *ex vivo* (n=129) or *in vivo* (n=89) after lesion identification during open biopsy. These techniques could be guaranteed to provide sufficient cells from the lesion and in addition, allowed the aspiration site to be identified at excision. Tissue from the aspiration site ( $3\text{mm}^3$ ) was collected for correlative histopathology. Prior to the  $^1\text{H}$  MRS experiment, each FNB specimen was thawed and transferred directly to a 5 mm MRS tube. The volume was adjusted to  $300\mu\text{l}$  with PBS/ $\text{D}_2\text{O}$  where necessary. The sample tube was fitted with a capillary insert containing  $60\mu\text{l}$  para-aminobenzoic acid (10 mM in PBS/ $\text{D}_2\text{O}$ ) as an external standard.

### B. CORRELATION WITH HISTOLOGICAL CRITERIA

#### Objective 3.

Identify MRS criteria to facilitate distinction between resected carcinoma and normal tissue.

*Rationale:* The primary data base will be obtained from this section of the study. The 1D and 2D MR data are likely to contain the majority of resonances that need to be assigned to chemical species, biological criteria and clinicopathological criteria.

**Results:** All pathological and MRS analyses were undertaken in a blinded study. Correlation of MRS data with clinicopathological criteria were made after all reports were filed. 218 FNB and tissue specimens for MRS analysis and correlative histopathology respectively were obtained from 191 consecutive patients undergoing diagnostic biopsy or definitive treatment (lumpectomy, quadrantectomy or mastectomy) for histologically proven invasive breast cancer. Indications for surgery included mammographically detected impalpable lesions as well as palpable mass lesions which were suspicious by mammography, FNA cytology and/or clinical examination. The age



range of patients was 20 to 81 years (mean  $\pm$  SD, 52  $\pm$  14). Where mastectomy for invasive carcinoma was performed, control specimens of macroscopically uninvolved breast tissue (which was later confirmed histologically) were obtained in the same patient (n=27). The MR experimental methods, data processing and analysis, peak assignment procedures and histopathological assessment protocols are described in detail in Appendix II.

Invasive carcinoma was identified by resonances at 3.25 ppm attributable to choline-containing metabolites (Appendix II, Figure 2). A discrimination between invasive carcinoma (n=82) and normal or benign tissue (n=106) was made based on the intensity of the 3.25 ppm resonance standardised to the resonance intensity at 3.05 ppm containing contributions from creatine, phosphocreatine and lysine ( $p < 0.0001$ , Mann-Whitney U test) (Appendix II, Figure 3). A receiver operating characteristic (ROC) curve using this intensity ratio is shown in Appendix I, Figure 4.

Of 106 benign samples, 102 gave a 3.25/3.05 ppm intensity ratio of less than 1.7. Four false positive results were obtained from 3 palpable fibroadenomas, none of which had FNA cytology performed, and 1 lesion comprising moderate ductal hyperplasia. The diagnoses were based on correlative histopathology. FNB from 4 of 82 carcinoma had a ratio of  $< 1.7$ . Correlative histopathology from the aspiration site showed that one sample had only benign fibrocystic changes in this region. The other three samples were confirmed as invasive carcinoma but with a marked inflammatory cell infiltrate.

**Clinical Correlations:** All cases presenting as mammographically suspicious (n=56), mammographically negative (n=23), or non-diagnostic (n=14) or atypical/suspicious (n=25) FNA cytology, were accurately categorised by MRS (as benign or malignant) as confirmed by histopathology on tissue excised from the aspiration site. MRS on F.B. correlated 96% with the final histological diagnosis of benign lesions (Appendix II, Table 2) and yet, biopsy was performed because of clinical (34%) and/or mammographic features (45%) and/or FNA cytology (31%). MRS on F.B. correlated with a malignant histological diagnosis in 95% of cases (Appendix II, Table 2). While combined triple assessment indicated biopsy for all the malignant cases studied, no single pre-operative modality was an improvement on MRS in identifying malignancy (physical examination 84%, mammography 82%, FNA cytology 92%).

#### Objective 4.

Establish whether MRS can identify differences between variants of breast cancer (e.g. lobular and ductal carcinoma) which reflect altered biological behaviour (e.g. likelihood of response to treatment or location of secondary tumours).

*Rationale:* Lobular and ductal carcinoma have quite different patient outcome. Ductal carcinoma will usually metastasise to the liver, brain, bone, lungs etc.. whereas lobular carcinoma frequently metastasises to unusual sites. If spectral differences exist between these two types of breast carcinoma and can be assigned to specific biological criteria e.g. altered cell surface glycosylation which could reflect altered immunosuppression (50), ability to lodge at different sites (51-53), or adhesion properties (54), the patient outcome could be rationalised at an early stage in the diagnosis and treatment altered accordingly. The reasons for variable survival of women with established metastatic disease may be manifest in the cellular chemistry of the carcinoma cells.

#### *Experimental:* Underway

#### Objective 5.

Correlate MRS properties with the established pathological characteristics of breast epithelial hyperplasia and neoplasia.



*Rationale:* It is important to identify which MRS characteristics are consistent with established pathological criteria. MRS will be used, as an adjunct to current histopathology, with each method contributing to a more thorough and refined diagnosis and patient management.

***Experimental:*** Underway

### **C. CAN MRS REDEFINE THE PRECURSOR STATES OF BREAST NEOPLASIA?**

Objective 6.

Compare simple hyperplasias, atypical hyperplasias and malignant tumours. Does MRS identify sub groups or categorise these histological states differently?

*Rationale:* The strength of the MR method as demonstrated in its application to other organs, was the identification of alterations to cellular chemistry which were not morphologically manifest, or which discriminated between subsets with overlapping or identical histological appearances (e.g. follicular adenoma and carcinoma of thyroid).

***Experimental:*** Underway

Objective 7.

Assess resected tissue containing morphological carcinoma *in situ* to determine if the MR method can separate those, if any, which contain cells committed to invasion from those that cannot progress at that time.

*Rationale:* Diagnosis of carcinoma *in situ* (CIS) of the human cervix relies on the pathologist confirming that the cells (which are morphologically indistinguishable from invasive cancer) have not invaded. MRS has clearly shown that CIS of the cervix does not have the same cellular chemistry as those cell which are invasive. Does CIS of the breast have a different cellular chemistry from invasive cells? Can the distinction be made between a CIS which has cellular capability to invade from those which have yet to develop fully invasive properties?

***Results:*** Specimens reported as ductal carcinoma-*in-situ* (DCIS) by routine hospital histopathology were obtained and assessed by MRS. Samples containing only DCIS (10 high grade, 1 low grade) all gave MR ratios  $\leq 1.7$  indicative of a low choline to creatine/lysine ratio similar to that obtained for benign lesions. Ductal cells had breached the basement membrane ( $< 1\text{mm}$ ) in one or more focus of the entire DCIS specimen in the 4 samples denoted 'microinvasion'. This group as well as 2 samples of high grade DCIS with extensive comedonecrosis gave ratios  $> 1.7$  similar to that obtained for malignant lesions.

### **D. CAN MRS IDENTIFY CHEMICAL PROFILES ASSOCIATED WITH A PREDISPOSITION TO BREAST CANCER?**

Objective 8.

Study morphologically normal tissue from women with differing risk factors for development of breast cancer.

*Rationale:* It is most likely that alterations to cellular chemistry are able to be documented in the above categories. Are there specific changes which can be identified in at-risk patients?

The effect of :-

age,  
pre vs post menopausal status,  
cyclic hormonal effects,  
genetic predisposition,  
family history,

on the spectral profile will be considered in a retrospective study in association with the breast data bank registries.

***Experimental: Underway.***

## **E. LONGITUDINAL STUDY**

Objective 9.

Statistical analysis to correlate MRS data with clinicopathological, epidemiological and genetic data.

***Rationale:*** By examining tissue specimens by MRS, it may be possible to predict the precise progression of breast cancer in individual patients more accurately than histopathology.

***Experimental: Underway***

## **METHODS** (*As in original submission*)

### **THE SELECTION OF PATIENTS**

Biopsy specimens are to be obtained at the time of surgery on 500 patients undergoing surgery to excise benign and malignant lesions by participating surgeons. The indications for surgery include:

1. Mammographically detected impalpable lesions where malignancy cannot be excluded. Stereotactic fine needle aspiration biopsy will be the indicator for surgery.

In this subgroup approximately 50% will have small invasive cancers, 30% of patients can be expected to have benign lesions such as sclerosing adenosis whilst the remainder will have premalignant conditions like atypical hyperplasia through to carcinoma *in situ*.

2. Excisions of mass lesions which have been proven by mammography, fine needle biopsy, cytology and clinical examination to be malignant where breast conservation can be performed. This is generally for patients with smaller tumours but is dependent upon other factors such as breast size.

The attending surgeon would undertake to provide this follow-up through out this period with regular reports to a central registry office. Initially, patients will be recruited to the study consecutively. However, it is anticipated that, as the study progresses, selection criteria may be introduced to enhance the data base of specific subgroups of patients.

### **THE PARTICIPATING SURGEONS**

#### **THE ROYAL ADELAIDE HOSPITAL**

South Australian clinical material in the first instance will be obtained from the patients treated by one surgeon (PLM) from the Breast Endocrine and Surgical Oncology Unit at the Royal Adelaide Hospital. This unit treats 200 primary or new breast cancers per year and provides a dedicated service to a 900 bed teaching hospital on the campus of the University of Adelaide. All patients are treated according to protocol and management is reviewed by a multidisciplinary team prior to treatment. Patients are regularly entered into Australian, New Zealand and international trials where appropriate. The routine pathology service is provided by pathologists from the Institute of Medical and Veterinary Science who also provide a dedicated service and attend the multidisciplinary meetings.

The unit is undertaking research in the following fields:

1. Endocrine responses to oestrogen and progesterone in breast cancer with particular reference to insulin-like growth factor binding proteins.
2. The immunological response associated with human breast cancer with reference to tumour infiltrating lymphocytes (TILs) boosted by lymphocyte growth factors.
3. The evaluation of magnetic resonance imaging of the breast in two subgroups of patients:
  - a) young women with dense parenchymal breast tissue
  - b) for the evaluation and accurate assessment of women with T3 breast cancers.
4. Dynamic doppler studies to evaluate vascular function in breast reconstruction using autologous tissues.
5. Angiogenesis in breast tumours determined by dynamic doppler.
6. A comparative study of carbon track localisation hook wire for mammographically detected impalpable breast lesions.
7. On-going evaluation of the following tumour markers: **a)** vimentin, **b)** cERB2, **c)** ER, **d)** PR, **e)** CA125, 153.
8. Open label study of high dose chemotherapy in patients with breast cancer using autologous

peripheral blood, stem cells and G-CSF support.

All patients treated by the unit are reviewed at regular intervals according to protocols and information provided to the Cancer Registry.

The unit works in close association with the South Australian Breast X-ray Service which screens 30,000 women per year between the ages of 40 - 69 years. From 1994 the number of women screened will increase to 45,000 per annum. This service provides a constant supply of small tumours as 70% of lesions detected by the clinic are less than 2 cm in size. This service is closely audited and offers the service to the point of diagnosis with particular emphasis upon stereotactic fine needle aspiration biopsy and ultrasound guided needle biopsy. The program is independently audited.

This service can provide biological material ranging through benign, premalignant, ductal carcinoma *in situ* and carcinoma.

### **WESTMEAD HOSPITAL**

The Breast Surgery Unit at Westmead Hospital is multidisciplinary involving all aspects of breast cancer patient care, with a major commitment to the management of patients with breast cancer irrespective of the stage of the disease at presentation. Approximately 150 patients with breast cancer are treated each year within the unit, with approximately 10% having advanced breast cancer and with an increasing number having *in situ* disease as the number of patients accessed through the Screening Unit increases.

The Unit is undertaking research in the following fields:

1. Since 1979 patients with operable breast cancer have had the option of a breast conservation approach involving 'lumpectomy', or 'quadrantectomy' with clear surgical margins, axillary clearance, and radiotherapy to the breast. A particular form of axillary clearance has been developed with improvements in the way the procedure can be taught to trainees and a video tape is in production and will be shown next year at surgical meetings of the Royal Australasian College of Surgeons.
2. Approximately 50 - 55% of the patients with operable breast cancer currently achieve breast conservation. An initial cohort of approximately 130 patients undergoing a breast preservation procedure have been followed and the results have been reported at 5 and 10 years. Patients needing mastectomy have been treated with total mastectomy and axillary clearance again using the axillary clearance technique developed by the unit.
3. A study has recently been completed to determine the value of the cERB2 antigen in predicting recurrence in node negative breast cancer patients followed for more than 5 years.
4. Apart from its own trials, the unit takes part in a number of international studies including the Zoladex trial for node positive breast cancer.
5. Ongoing evaluation of the following markers is being undertaken: **a)** ER, **b)** PR, **c)** ploidy, **d)** epidermal growth factor receptors.

The surgical team works closely with Radiation and Medical Oncologists, with the Breast Screening Unit and with the Cytology and Pathology Departments. Combined clinics are held and a major Breast Cancer Data Base has been established within the Radiation Oncology Department. Reports have been published on the efficacy of cytology prior to breast surgery, on the problems encountered with the procedures involved in breast conservation, and also the results from our 'Advanced Protocol Treatment' of advanced breast cancer at presentation. The senior surgeon is also the senior surgeon of the Screening Unit which now has considerable expertise in all aspects of Screening, and is recognised as a training unit for medical and paramedical professionals involved with Breast Screening. Surgical and radiotherapy trainees take part in the clinical program and for the past 12 months a 'Breast Fellow' has been appointed and this is a recognised post for the Royal Australasian College of Surgeons for postgraduate training breast surgery for young surgeons who have achieved Fellowship of the Royal Australasian College of Surgeons.

This service can provide biological material ranging through benign, premalignant, ductal carcinoma *in situ* and carcinoma.

### **CONCORD HOSPITAL**

The Breast Endocrine Unit at Concord Hospital was established in 1986. It is composed of four dedicated surgeons working from a forty bed unit. It is closely associated with the University of Sydney and is involved in student teaching, registrar training and research.

Approximately 100 cases are seen per annum. The data collection is made on a standard protocol and processed using computer programs.

The unit is associated with the breast screening clinics of Central and Western Sydney. The principals attend these clinics and patients are then referred for treatment at Concord Hospital.

Multi-disciplinary meetings involving pathologists, radiologists and surgeons are held on a regular basis and a routine monthly review of all cases is undertaken. Standard protocols for breast treatment have been instituted and are followed by the treating surgeons.

Papers have been published on the accuracy of fine needle aspiration cytology in breast cancer patients, the incidence of mammography negative breast cancers seen through the clinic and the incidence of multi focal breast cancer.

This service can provide fewer specimens than the larger two centres but a strong collaboration between the MR Unit and surgeons at Concord Hospital is well established.

### ***MAGNETIC RESONANCE SPECTROSCOPY***

**Sample Handling** Tissues obtained at surgery will be placed into a sterile tube containing pre-cooled (4 C) phosphate buffered saline in D<sub>2</sub>O (PBS/D<sub>2</sub>O) immediately after excision. Alternatively, biopsies will be snap frozen in liquid nitrogen, transported to the laboratory and stored at -70 C until ready for examination. Samples to be examined by MRS will be gently thawed, washed in PBS/D<sub>2</sub>O (5 x 1 ml) and placed in a 5 mm MR tube containing sufficient PBS/D<sub>2</sub>O to cover the biopsy. Placement within the transmitter/receiver coil will be ensured by either resting the biopsy on top of a plug of glass wool (5), or by suspending the biopsy inside an inner capillary tube of 2.5 mm diameter (10,34). In the case of the capillary method, the external volume will be filled with 350 µl of 1 mM p-aminobenzoic acid (PABA) in PBS/D<sub>2</sub>O which serves as a chemical shift and concentration reference (34). As in the case of colorectal biopsies (21), prior to the MRS experiment the specimens will have excess adipose tissue and vasculature excised. Alternative methods such as passing the tissue through a metal sieve to trap the fat (see Page 17) will be explored.

**F.B.:** will be performed using 5 aspirated passes through the specimen with a 21 gauge needle (39). Previous studies (55) have shown that this combination gives the greatest number of cells, both single and in clumps, although it is not the preferred technique if clear cellular detail is required for accurate cytological examination. F.B. are washed with 2 x 1 ml PBS/D<sub>2</sub>O. Between washes the samples are centrifuged (1000g for 5 min) and the supernatant discarded. The F.B. are suspended in PBS/D<sub>2</sub>O (final volume 125 µl) and then placed on top of a glass wool plug in a 5 mm MRS tube.

**Data Collection** Data will be collected on a Bruker AM360 wide-bore MR spectrometer equipped with an Aspect 3000 computer and a dedicated 5 mm or 8 mm <sup>1</sup>H probe. Temperature is maintained at 37 C using a Bruker VT1000 temperature regulation unit.

**Pulse Sequences** All pulse sequences to be used are functional in this laboratory at the time of application. Typical experiments are as follows:-

**1D <sup>1</sup>H spectroscopy:** 1D spectra (at 360 MHZ) are obtained using a spectral width of 3600 Hz (10 ppm) and 8K data points. A relaxation delay of 2 sec is used during which gated decoupling (15 dB below 0.2 W) is applied for the final 1 sec to reduce the residual water signal (56). 128 transients are averaged.

**CPMG:** One-dimensional  $T_2$ -filtered experiments are performed using the Carr-Purcell-Meiboom-Gill pulse sequence ( $90_x - (-180_y - )_n$ -acquire) with an interpulse delay of  $\tau = 1$  msec and a 2 sec relaxation delay between acquisitions (48). Gated presaturation is used in the final 1 sec before data acquisition. 128 transients are collected using a spectral width of 10 ppm.  $T_2$ -filtered 1D experiments on biopsy specimens is performed using selected values of  $n$ . Typical values of  $n_2 = 16, 480, 720, 960$  ms.

**2D  $^1H$ - $^1H$  COSY spectroscopy:** Magnitude-mode COSY spectra are performed using a standard two pulse sequence with the two pulses separated by an incremented delay (57). The sweep width in the  $t_2$  domain is 3000 Hz, and the size in the  $t_2$  domain is 2K data points. The initial delay between the 2 pulses is 1 msec with an increment time of 334 sec. There is a relaxation delay of 1 sec before each accumulation during which the water resonance is presaturated using a CW irradiation power of 30 dB below 0.2 W. The number of time domain points collected in  $t_1$  (free induction decays, FIDs) is subject to the viability limits of the sample. Tissue experiments consist of 180-220 FIDs, each of 32-48 transients (plus 2 dummy scans) over a total experiment time of three to five hours.

**$T_2$ -filtered CORrelation Spectroscopy:**  $T_2$ -filtered correlation spectra are obtained by replacing the first pulse of a standard COSY pulse sequence with a CPMG sequence (48). Typical parameters are described above with  $n_2$  equal to 500 - 750 msec. The sequence removes crosspeaks arising from short  $T_2$  species, like lipid, leaving only resonances from more mobile metabolites. The pulse sequence is useful in resonance assignment in specimens, like breast, which contain large quantities of lipid that can be reduced or removed using this technique.

**Processing of MRS Data** Data will be processed on a Bruker X32 (UNIX) Data Station. The complexities of processing FIDs from biological material containing a wide range of  $T_2$  relaxation values (0.3 - 1.5 s) has been addressed in this laboratory (17). The processing parameters vary according to the MR visible chemicals of each tissue type.

**1D spectroscopy:** One dimensional spectra (1D and CPMG) are routinely processed using a line broadening of 3 Hz applied before Fourier transformation. Data are phase corrected using zero and first order phase correction and baselines are corrected using a fourth order polynomial baseline correction routine. Linewidths or ratios of peak heights are measured in 1D spectra.

**2D spectroscopy:** COSY data matrices undergo zero filling to 1K in  $t_1$ , Fourier transformation and magnitude calculation (  $(\text{Real}^2 + \text{Imaginary}^2)$  ) to give 1024 x 1024 real data points for each COSY spectrum. Sine-bell window functions are uniformly applied in the  $t_1$  domain and Lorentzian-Gaussian window functions of varying width and maximum positions are applied in the  $t_2$  domain prior to Fourier transformation as previously described (17). Crosspeak volumes and subsequent ratios to external or internal reference peaks will be measured as previously described (2,7,8,58).

Referencing peak height integrals, or peak heights, to those of an external standard with a constant concentration and  $T_2$  relaxation value allows a semi quantitative concentration measurement. However, differences in crosspeak volumes can arise from either concentration changes or from changes in  $T_2$  relaxation of the species. These two effects cannot be separated, but an increase in crosspeak volume will reflect either a chemical change or a reorganisation of the compound within the cell, and may still have diagnostic relevance.

## **MATHEMATICAL ANALYSIS OF MR DATA FROM THE UNIX**

Unprocessed MRS data will be transferred electronically via internet to the Silicon Graphics server at the Institute for Biodiagnostics, Winnipeg, Canada for a thorough mathematical analysis. The MR spectra will be prepared for analysis by means of the proprietary software ALLFIT (National Research Council of Canada), which provides appropriate baselines and integrals for each distinguishable peak. The spectra will then be preprocessed by formation of a correlation matrix to avoid problems due to widely disparate variate ranges. Principal component analysis will then be applied to the spectral regions of interest, in order to reduce the number of variable in the computation. One half the available data will be used as a training set, and the remaining half will be classified blindly. To make all analyses robust,

the training set data will be analysed by the leave-one-out method *i.e.* train on k-1 of the k samples, classify the sample that was excluded from the training set, and repeat this k times, once for each sample.

Classification will be performed by a variety of methods, alone and in combination. The principal methods are linear and quadratic discriminant analysis (45), neural nets of various types (44), and genetic programming (46). Consensus analysis will be performed within each method using different regions of the spectrum and with combinations of methods, to increase accuracy of classification. Fuzzy logic methods will be applied where appropriate.

## **HISTOPATHOLOGY**

Every MR sample will be assessed by one of two pathologists.

***Expertise of the Pathologists*** The two pathologists participating in this study are Senior Hospital Consultants, each with over 25 years experience. Professor P. Russell is an acknowledged authority (59) and Dr J. Phillips is well recognised internationally in the field of aspiration cytology. Each pathologist has indicated that he/she is willing and able to make the necessary contribution in time to ensure the success of this project.

### ***Rationale for the Extent of Histological Assessment***

1. Primary correlation is obtained by comparing the MRS result with standard hospital histopathological diagnosis. This involves no additional time spent by the pathologist. Long-term storage of fixed tissue for later re-examination will be required.
2. The MRS sample is always examined **initially** by six "step-sections" 7µm sections (taken at 350 µm intervals) at x 40 magnification. The intervening sections are mounted, stained and stored for future assessment if required. Tissue preservation, cellular content and presence of potentially confounding factors such as fat and inflammatory cells are reported in addition to the diagnosis. This involves an additional 5-6 minutes of pathologist time per specimen and is undertaken without reference to clinical or MRS data (in both MRS specimens and remainder of surgical specimen).
3. Where disagreement exists between MRS diagnosis and histological diagnosis, the MRS sample will be step-serially sectioned every 7 µm (refer to 2) and examined by the pathologist in a blind study. To avoid bias other specimens will be included at the same time.

### ***Tissue Preparation***

**Routine:** Tissue is fixed in 10% buffered formalin or FAA (formalin:acetic acid:alcohol), paraffin embedded and sectioned, stained with haematoxylin and eosin according to standard protocols.

**Serial sectioning:** Routine sectioning of paraffin blocks will be at 7 µm. Step serial sectioning of paraffin blocks will be undertaken on selected specimens.

***Criteria for establishing firm histological diagnosis of cancer and its precursors in the tissues to be included in this study, will follow established guidelines.*** In general terms, the various pathological subtypes of cancer will be classified according to the relevant WHO International Histological Tumour Classification and, where difficult diagnostic problems are encountered (particularly for borderline malignancies), the guidelines in the following reference text will be used *viz* Page D.L. & Anderson T.J. (1990) Diagnostic Histopathology of the Breast. Churchill Livingstone, United Kingdom.

***Quantification of Cell Types*** This will be performed usually on 'step' or 'full' serial sections and is only intended to provide an approximate guide to relative proportions of study tissues to background stroma and reactive inflammatory infiltrates etc.



## ***STATISTICAL ANALYSIS***

The epidemiologist (O.D.) in Canberra will examine associations statistically between MRS assessment and pathology and clinical variables using comparisons between means, contingency tables and logistic regression. Associations between MRS spectra and patient survival will be assessed by Kaplan - Meier Survival analysis (60) and proportional hazards regression models (61).

## **CONCLUSIONS**

- **This project is proceeding as outlined in the original document and as described above.**
- **Of the three “purposes” listed on page 4 the first two are well underway.**
- **Hypotheses 1 and 2 (page 4) have been shown to be correct. Data collected so far indicate that hypothesis 4 is also correct.**
- **No unforeseen difficulties have been encountered and the program is proceeding to schedule.**

## REFERENCES (as in original document)

1. Ferenczy A, Winkler B (1987): *In: Blaustein's Pathology of the Female Genital Tract*, Kuman RJ (ed). Springer-Verlag, New York, Chap. 8, pp.218-256.
2. Mountford CE, Lean CL, Mackinnon WB, Russell, P (1993a): The use of proton MR in cancer pathology, in: *Annual Reports on NMR spectroscopy*, (ed.) G.A. Webb, Academic Press, Vol 27, pp. 173-215.
3. Cross KJ, Holmes KT, Mountford CE, Wright PE (1984): Assignment of acyl chain resonances from membranes of mammalian cells by two-dimensional NMR methods. *Biochemistry* 23:5895-5897.
4. May GL, Wright LC, Holmes KT, Williams PG, Smith, ICP, Wright PE, Fox RM, Mountford CE (1986): Assignment of methylene proton resonances in NMR spectra of embryonic and transformed cells to plasma membrane triglyceride. *J. Biol. Chem.* 261:3048-3053.
5. Mountford CE, Delikatny EJ, Dyne M, Holmes KT, Mackinnon WB, Ford R, Hunter JC, Truskett ID, Russell, P (1990): Uterine cervical punch biopsy specimens can be analysed by  $^1\text{H}$  MRS. *Magn. Reson. Med.* 13:324-331.
6. Sze DY, Jardetzky O (1990): Determination of metabolite and nucleotide concentrations in proliferating lymphocytes by  $^1\text{H}$  NMR of acid extracts. *Biochim. Biophys. Acta*, 1054:181-197.
7. Lean CL, Mackinnon WB, Mountford CE (1991): Fucose in  $^1\text{H}$  COSY spectra of plasma membrane fragments shed from human malignant colorectal cells. *Magn. Reson. Med.* 20:306-311.
8. Lean CL, Mackinnon WB, Delikatny EJ, Whitehead RH, Mountford CE (1992): Cell surface fucosylation and magnetic resonance spectroscopy characterization of human malignant colorectal cells. *Biochemistry* 31:11095-11105.
9. Mackinnon WB, May GL, Mountford CE (1992a): Esterified cholesterol and triglyceride are present in plasma membranes of Chinese hamster ovary cells. *Eur. J. Biochem.* 205:827-839.
10. Delikatny EJ, Russell P, Hunter JC, Hancock R, Atkinson K, van Haaften-Day C, Mountford CE (1993): Proton MR and human cervical neoplasia. I. *Ex vivo* spectroscopy allows distinction of invasive carcinoma of the cervix from carcinoma *in situ* and other preinvasive lesions. *Radiology* 188:791-796.
11. Russell P, Lean CL, Delbridge L, May G, Dowd S, Mountford CE (1994): Proton magnetic resonance and human thyroid neoplasia. I: Discrimination between benign and malignant follicular thyroid neoplasms by magnetic resonance spectroscopy. *Am J. Med.* 96:383-388.
12. Mountford CE, Saunders JKS, May GL, Holmes KT, Williams PG, Fox RM, Tattersall MHN, Barr JR, Russell P, Smith ICP (1986): Classification of human tumours by high-resolution magnetic resonance spectroscopy. *The Lancet* i:651-654.
13. Mountford CE, Tattersall MHN (1987): Proton magnetic resonance spectroscopy and tumour detection, in: *Cancer Surveys*, 6:285-314.
14. Mackinnon WB, Russell P, May GL, Mountford CE (1993): Cell surface fucosylation identifies human ovarian serous epithelial tumours. *Proc. Soc. Magn. Reson. Med.* 3:1156.
15. May GL, Wright LC, Dyne M, Mackinnon WB, Fox RM, Mountford CE (1988): Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts. *Int. J. Cancer* 42:728-733.
16. Mountford CE, Mackinnon WB, Bloom M, Burnell EE, Smith ICP (1984): NMR methods for characterizing the state of the surfaces of complex mammalian cells. *J. Biochem & Biophys Meth.* 9:323-330.

17. Delikatny EJ, Hull WE, Mountford CE (1991): The effect of altering time domains and window functions in two-dimensional proton COSY spectra of biological specimens. *J. Magn. Reson.* 94:563-573.
18. Hakomori S (1989): Aberrant glycosylation in tumours and tumour-associated carbohydrate antigens. *Adv. Cancer Res.* 52:257-331.
19. Kim YS, Yuan M, Itzkowitz SH, Sun Q, Kajzu T, Palekar A, Trump BF, Hakomori S (1986): Expression of Le<sup>y</sup> and extended Le<sup>y</sup> blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissue. *Cancer Res.* 46:5985-5992.
20. Wright LC, May GL, Gregory P, Dyne M, Holmes KT, Williams PG, Mountford CE (1988): Inhibition of metastatic potential by fucosidase: an NMR study identifies a cell surface metastasis marker. *J. Cell. Biochem.* 37:49-59.
21. Lean CL, Newland RC, Ende PA, Bokey EL, Smith ICP, Mountford CE (1993a): Assessment of human colorectal biopsies by <sup>1</sup>H MRS: correlation with histopathology. *Magn. Reson. Med.* 30:525-533.
22. Leibovitz A, Stinson JC, McCoombs (III) WB, McCoy CE, Mazur KC, Mabry ND (1976). Classification of human colorectal adenocarcinoma cell lines. *Cancer Res.*, 36:4562-4569.
23. Whitehead RH, Macrae FA, St. John DJB, Jeng MA (1985): A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. *J. Natl. Cancer Inst.* 74:759-765.
24. Rutzky LP (1984): The biology of human colon tumor cells in culture. *Adv. in Cell Culture*, 4:47-83.
25. Whitehead RH, Jones JK, Gabriel A, Lukeis RE (1987): A new colon carcinoma cell line (LIM1863) that grows as organoids with spontaneous differentiation into crypt-like structures *in vitro*. *Cancer Res.* 47:2683-2689.
26. Paraskeva C, Buckle BG, Sheer D, Wigley CB (1984): The isolation and characterization of colorectal epithelial cell lines at different stages in malignant transformation from familial polyposis coli patients. *Int. J. Cancer* 34:49-56.
27. Paraskeva C, Finerty S, Powell S (1988): Immortalization of a human colorectal adenoma cell line by continuous *in vitro* passage: possible involvement of chromosome 1 in tumour progression. *Int. J. Cancer*, 41:908-912.
28. Williams AC, Harper SJ, Paraskeva C (1990): Neoplastic transformation of a human colonic epithelial cell line: *in vitro* evidence for the adenoma to carcinoma sequence. *Cancer Res.* 50:4724.
29. Mackinnon WB, Lean C, Hancock R, Huschtscha L, Mountford CE (1992b): Cell surface fucosylation reflects loss of cellular differentiation in human colorectal cancer. *Proc. Soc. Magn. Reson. Med.* 2:3531.
30. Mackinnon WB, Huschtscha LI, Dent K, Hancock R, Paraskeva C, Mountford CE. (1994) Cellular differentiation in human colorectal carcinoma and adenoma cell lines reflected in proton magnetic resonance spectra *Int. J. Cancer* 59:248-261.
31. Ende D, Lean C, Mackinnon W, Bokey EL, Chapuis P, Newland R, Mountford C (1993a): Colorectal tissues assessed *ex vivo* by proton magnetic resonance spectroscopy, *Proc. Tripartite Colorectal Surgery Meeting*, Sydney.
32. Ende DA, Lean CL, Mackinnon WB, Chapuis P, Newland R, Russell P, Bokey EL, Mountford CE (1993b): Human colorectal adenoma-carcinoma sequence documented by <sup>1</sup>H MRS (*ex vivo*). *Proc. Soc. Magn. Reson. Med.* 2:1033.
33. Somorjai RL, Nikulin AE, Kuesel AC, Prefontaine M, Mikhael N, Smith ICP (1992): Classification of cervical biopsies based on <sup>1</sup>H NMR spectral information using feature extraction methods. *Proc. Soc. Magn. Res. Med.* p.56.
34. Kuesel AC, Kroft T, Saunders JK, Prefontaine M, Mikhael N, Smith ICP (1992): A simple procedure for obtaining high quality NMR spectra of semiquantitative value from small tissue

- specimens. *Magn. Reson. Med.* 27:349-355.
35. Kunnecke BE, Delikatny EJ, Hunter JC, Russell P, Mountford CE (1994): Proton magnetic resonance and human cervical neoplasia II: *Ex vivo* chemical shift imaging. *J. Magn. Reson.* 104B:135-142.
36. Fearon ER, Vogelstein B (1990): A genetic model for colorectal tumorigenesis. *Cell* 61:759-767.
37. Mazzaferri EL (1993): Management of the solitary thyroid nodule. *New Eng. J. Med.* 328:553.
38. Delbridge L, Lean CL, Russell P, May GL, Roman S, Dowd S, Reeve TS, Mountford CE (1994): Proton magnetic resonance and human thyroid neoplasia. II: Potential avoidance of surgery for benign follicular neoplasms. *World J. Surg.* 18:512-517.
39. Lean CL, Delbridge L, Russell P, May GL, Roman S, Fahey III TJ, Dowd S, Mountford CE. (1995) Proton magnetic resonance and human thyroid neoplasms II: diagnosis of benign follicular adenomas by fine needle biopsy. *J. Clin. Endocrin. & Med.* 80:1306-1311.
40. Rutter A, Kunnecke B, Russell P, Delbridge L, Mountford CE. (1995) Proton magnetic resonance and human thyroid neoplasia III: *Ex vivo* chemical shift microimaging *J. Mag Res.* B110:240-248.
41. Mountford CE, Lean CL, Hancock R, Dowd S, Mackinnon WB, Tattersall MHN, Russell P (1993b): Magnetic resonance spectroscopy detects cancer in draining lymph nodes *Inv. Metastasis* 13:57-71.
42. Daly PF, Cohen JS (1989): Magnetic resonance spectroscopy of tumors and potential *in vivo* clinical applications: a review. *Cancer Res.* 49:770-779.
43. Krzanowski WJ (1988): *Principles of Multivariate Analysis - A User's Perspective* Oxford Science Publications, Clarendon Press, Oxford.
44. Hertz J, Krogh A, Palmer RG (1991): *Introduction to the Theory of Neural Computation.* Addison- Wesley Publishing Co., Redwood City, California.
45. Lachenbruch PA (1975): *Discriminant Analysis* Hafner press, London.
46. Koza JR (1992): *Genetic Programming* MIT Press, Cambridge, Massachusetts.
47. Somorjai RL, Pizzi N, Nikulin A, Jackson R, Mountford CE, Russell P, Lean CL, Delbridge L, Smith ICP (1993): Thyroid neoplasms: classification by means of consensus multivariate analysis of <sup>1</sup>H MR spectra. *Proc. Soc. Magn. Res. Med.* 1:72.
48. Williams P, Saunders JK, Dyne M, Mountford CE, Holmes KT (1988): Application of a T<sub>2</sub>-filtered COSY experiment to identify the origin of slowly relaxing species in normal and malignant tissue. *Magn. Reson. Med.* 7:463-471.
49. Lean CL, Russell P, Delbridge L, May GL, Dowd S, Mountford CE (1993b): Metastatic follicular thyroid diagnosed by <sup>1</sup>H MRS (*ex vivo*). *Proc. Soc. Magn. Res. Med.* 1:71.
50. Yoogeswaran G, Granberg A, Welsh RM, Kiessling R (1983): Interferon induced increase in neuraminidase-releasable sialic acid and glycosphingolipid metabolism in mouse lymphoma and L1210 leukemic cell lines: correlation with susceptibility to natural killer cell-mediated lysis. *Int. J. Cancer* 31:501-507.
51. Bolscher JGM, Schallier DCC, Smets LA, van Rooy H, Collard JG, Bruyneel EA, Mareel MMK (1986): Effect of cancer related and drug induced alterations in surface carbohydrates on the invasive capacity of mouse and rat cells. *Cancer Res.* 46:4080-4086.
52. Dennis JW, Laferte S (1987): Tumor cell surface carbohydrate and the metastatic phenotype. *Cancer Metastasis Reviews* 5:185-204.
53. Bresalier RS, Rockwell RW, Dahiya R, Duh QY, Kim YS (1990): Cell surface sialoprotein alterations in metastatic murine colon cancer cell lines selected in an animal model for colon cancer metastasis. *Cancer Res.* 50:1299-1307.
54. Schirrmacher V, Altevoigt P, Fogel M, Dennis J, Waller CA, Barz D, Schwartz R, Cheingsong-Popov R, Springer G, Robinson PJ, Nebe T, Brossmer W, Vlodavsky I, Paweletz N, Zimmerman H-P, Uhlenbruck G (1982): Importance of cell surface carbohydrates in cancer cell adhesion. *Invasion Metastasis*, 2:313-360.

55. Fagin JA, Matsuo K, Karmaker A, Chen DL, Tang S, Koeffler HP (1993): High prevalence of mutations of p53 gene in poorly differentiated human thyroid carcinomas. *J. Clin. Invest.* 91:179-184.
56. Jesson JP, Meakin P, Kneissell G (1973): Homonuclear decoupling and peak elimination of Fourier Transform nuclear magnetic resonance. *J. Amer. Chem. Soc.* 95:618-620.
57. Bax A, Freeman R (1981): Investigation of complex networks of spin-spin coupling by two-dimensional NMR. *J. Magn. Reson.* 44:542-561.
58. Dingley AJ, King NJC, King GF (1992): An NMR investigation of the changes in plasma membrane triglyceride and phospholipid precursors during the activation of T-lymphocytes. *Biochemistry* 31:9098-9106.
59. Russell P, Bannatyne P (1989): *In: Surgical Pathology of the Ovaries*. Churchill Livingstone, Edinburgh, Chapters 22 - 31, pp.190-314.
60. Kaplan EL, Meier P (1958): Nonparametric estimation from incomplete observations. *J. Amer. Stat. Assoc.* 53:457-481.
61. Cox DR (1972): Regression models and life tables. *J. Roy. Stat. Soc. [B]* 34:187-202.

## ACRONYM /SYMBOL DEFINITION

<b>1D</b>	-	one dimensional
<b>2D</b>	-	two dimensional
<b><math>^1\text{H}</math></b>	-	proton
<b>12p</b>	-	chromosome 12 p (short) arm
<b>18q</b>	-	chromosome 18 q (long) arm
<b>CA125</b>	-	tumour marker
<b>CA153</b>	-	tumour marker
<b>cERB2</b>	-	tumour marker
<b>CH/CH<sub>2</sub></b>	-	methine to methylene ratio
<b>CH<sub>2</sub>/CH<sub>3</sub></b>	-	methylene to methyl ratio
<b>CIN</b>	-	cervical intraepithelial neoplasia
<b>CINI</b>	-	cervical intraepithelial neoplasia - stage I
<b>CINII</b>	-	cervical intraepithelial neoplasia - stage II
<b>CINIII</b>	-	cervical intraepithelial neoplasia - stage III
<b>CIS</b>	-	carcinoma <i>in situ</i>
<b>CPMG</b>	-	Carr-Purcell-Meiboom-Gill
<b>COSY</b>	-	COrelated Spectroscopy
<b>CW</b>	-	continuous wave
<b>dB</b>	-	decibel
<b>D<sub>2</sub>O</b>	-	deuterium oxide
<b>ER</b>	-	oestrogen receptor
<b>f<sub>1</sub> and f<sub>2</sub></b>	-	frequency in the first and second dimensions of a 2D MR experiment
<b>FAA</b>	-	formalin:acetic acid:alcohol
<b>FID</b>	-	free induction decay
<b>FNB</b>	-	fine needle biopsy
<b>Fuc</b>	-	fucose
<b>GB</b>	-	Gaussian broadening
<b>G-CSF</b>	-	granulocyte colony stimulating factor
<b>H<sub>5</sub>-H<sub>6</sub></b>	-	coupling between protons attached to the C <sub>5</sub> and C <sub>6</sub> of carbohydrate moieties



<b>Hz</b>	-	Hertz
<b>K-<i>ras</i></b>	-	oncogene
<b>LB</b>	-	Lorentzian broadening
<b>Le<sup>y</sup></b>	-	Lewis <sup>y</sup> (antigen)
<b>MHz</b>	-	mega Hertz
<b>MRI</b>	-	magnetic resonance imaging
<b>MRS</b>	-	magnetic resonance spectroscopy
<b>MR</b>	-	magnetic resonance
<b>NRC</b>	-	National Research Council of Canada
<b>p53</b>	-	tumour suppressor gene
<b>PABA</b>	-	p-aminobenzoic acid
<b>PBS</b>	-	phosphate buffered saline
<b>PCA</b>	-	principal component analysis
<b>ppm</b>	-	parts per million (units of chemical shift)
<b>PR</b>	-	progesterone receptor
<b>SFNAB</b>	-	stereotactic fine needle aspiration biopsy
<b>t<sub>1</sub> and t<sub>2</sub></b>	-	first and second time domains in a 2D MR experiment
<b>T1</b>	-	tumour size less than 2 cm
<b>T2</b>	-	tumour size 2 - 5 cm
<b>T3</b>	-	tumour size greater than 5 cm
<b>T<sub>2</sub></b>	-	spin-spin (transverse) relaxation
<b>Thr/Fuc</b>	-	threonine/fucose
<b>TIL</b>	-	tumour infiltrating lymphocytes

**FINE NEEDLE BIOPSY OF BENIGN BREAST LESIONS  
DISTINGUISHED FROM INVASIVE CANCER EX VIVO BY  
PROTON MAGNETIC RESONANCE SPECTROSCOPY**

Wanda B. Mackinnon, PhD, Peter Barry, MB BS, +Peter Malycha, FRACS,  
†David Gillett, MS, FRACS, Peter Russell, MD, FRCPA, Cynthia L. Lean, PhD,  
Sinead Doran, B.Sc.(Hons), §Bruce Barraclough, FRACS, DDU,  
¥Michael Bilous, FRCPA, and Carolyn E. Mountford\*, D.Phil.

Institute for Magnetic Resonance Research,  
University of Sydney, N.S.W. 2006, Australia.

+Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia 5000

†Department of Surgery, Repatriation General Hospital, Concord, N.S.W. 2137,  
Australia

§Departments of Surgery and ¥Anatomical Pathology, Westmead Hospital,  
Sydney, N.S.W. 2145, Australia.

This work was supported by NH&MRC Project Grant 950215.

**Running Title:** Breast pathology identified on FNB by Proton MRS.

\*To whom correspondence should be addressed.

Fax: 612 - 9351-4105      email: caro@medicine.su.oz.au

**ABSTRACT**

**PURPOSE** To prospectively determine whether conventional unlocalized proton magnetic resonance spectroscopy ( $^1\text{H}$  MRS) *ex vivo* can distinguish invasive breast cancer from benign lesions based on altered cellular chemistry.

**MATERIALS AND METHODS** Fine Needle Biopsies (FNB) (n=218) were obtained from patients undergoing breast surgery and analysed by proton MR spectroscopy at 360MHz (8.5 Tesla) and results compared with histopathological analysis. The results of blinded MR analysis were compared with currently employed diagnostic approaches used in assessment of breast lesions.

**RESULTS** Invasive carcinoma was identified spectroscopically by an increased signal at 3.25 parts per million (ppm) attributable to choline-containing metabolites. Discrimination between invasive carcinoma (n=82) and normal or benign (n=106) or carcinoma *in situ* (n=17) was made based on the intensity of the 3.25 ppm resonance standardised to the resonance intensity at 3.05 ppm ( $p < 0.0001$ , Mann-Whitney U test). An MRS ratio of  $< 1.7$  was recorded for 102 out of 106 normal or benign lesions. All carcinoma-*in-situ* samples with comedonecrosis or a microinvasive component (n=6) were ranked by MRS with invasive carcinoma while those with *in-situ* disease alone ranked with benign (n=11). The sensitivity and specificity of MRS on FNB for benign versus invasive breast cancer was 95% and 96% respectively.

**CONCLUSION**  $^1\text{H}$  MRS on FNB provides objective diagnostic information which potentially complements conventional pre-operative investigations in women with breast lesions.

**Key Words:**

nuclear magnetic resonance

carcinoma *in situ*

breast cancer

fine needle aspiration

cytology

## INTRODUCTION

In Australia, breast cancer is the leading cause of cancer-related death in women. Its incidence outranks all other cancers in women over age 35 years. In the past decade, the incidence rose by 25% and the life-time risk (from 0-74 years) for white women developing breast cancer is comparable to Western world figures at 1 in 13.

Recent improvement in breast cancer patient outcome is due to earlier diagnosis and more effective management.<sup>1,2</sup> A combination of physical examination, mammography and fine needle aspiration cytology (triple assessment) is to date the most sensitive method for pre-operative diagnosis of clinical and radiographically detected breast lesions. While triple assessment has a high probability of detecting all malignant lesions, its sub-optimal specificity results in diagnostic uncertainty requiring open biopsy to exclude malignancy in many women.

Physical examination has limitations due to individual variation in breast consistency, the site and size of the lesion (less than 1 cm is usually impalpable), and the presence of a diffuse versus discrete tumour. Screening mammography guidelines ensure that approximately one benign lesion is biopsied for every malignant lesion detected.<sup>3</sup> Even so, 10 - 40% of palpable breast cancers are missed on mammography alone, especially in women under 50 years of age in whom radiographically dense breast tissue may obscure changes associated with malignancy.<sup>4-7</sup> Fine Needle Aspiration cytology (FNA) has a sampling error rate in the range of 1 to 15%.<sup>8</sup> partly explaining its varied sensitivity. While the complete sensitivity of FNA is 81-97%,<sup>9</sup> this includes atypical and suspicious diagnoses which typically lead to the histological confirmation of cancer by open biopsy in 50 to 80% of cases.<sup>10</sup>

A technology which monitors cellular chemistry which correlates with different cell behaviour could offer both independent and objective assessment of breast tissue. The potential then exists to identify a predisposition towards or early features of breast cancer and thus offer interventions aimed at reducing tumour development. Proton Magnetic Resonance Spectroscopy (MRS) is one diagnostic

modality which has been successfully applied to monitor tumour development and progression in other organs.<sup>11-17</sup> Proton MRS can distinguish pre-invasive from invasive cancer of the uterine cervix with a sensitivity and specificity of 98% and 94% respectively<sup>12</sup>. The technique also distinguishes genuinely benign from malignant follicular lesions in human thyroid<sup>17</sup> and discriminates degrees of loss of cellular differentiation in ovarian tumours.<sup>15</sup>

Preliminary investigations of excised breast tissue by unlocalized one- and two-dimensional proton MRS detected increased levels of glycerophosphocholine and phosphocholine in invasive breast carcinoma compared with benign fibroadenomas.<sup>18</sup> Specimens of benign fibrocystic disease were characterised by an absence of resonances from choline, amino acids and other metabolites. However, a major difficulty was experienced in obtaining adequate spectral resolution from excised breast due to the high adipose content of the tissue. The intense broad MR resonances from this fat often masked other diagnostic resonances in the one-dimensional spectrum. This problem is largely overcome by applying a T<sub>2</sub> filter (Carr-Purcell-Meiboom-Gill sequence) during data collection<sup>19</sup> and/or with post-acquisitional data processing.<sup>20</sup> A simpler remedy was to optimise specimen collection. Collection procedures were found to substantially affect the amounts of exogenous fat sampled. Fine needle aspiration biopsy methods developed for thyroid sampling<sup>16</sup> provided cellular material adequate for assessment by MRS with reduced fat levels compared with excised tissue.<sup>21</sup>

Our objectives for this study were 1) to assess the sensitivity and specificity of <sup>1</sup>H MRS for delineating invasive breast cancer *ex vivo* on FNB, 2) to determine whether carcinoma *in-situ* could be distinguished from invasive carcinoma and 3) to compare diagnosis by MRS on FNB with traditional pre-operative investigations such as physical examination, mammography and FNA cytology.

## MATERIALS AND METHODS

All pathological and MRS analyses were undertaken in a blinded study. Correlation of MRS data with clinicopathological criteria were made after all reports were filed.

### ***Patients***

218 FNB and tissue specimens for MRS analysis and correlative histopathology respectively were obtained from 191 consecutive patients undergoing diagnostic biopsy or definitive treatment (lumpectomy, quadrantectomy or mastectomy) for histologically proven invasive breast cancer. Indications for surgery included mammographically detected impalpable lesions as well as palpable mass lesions which were suspicious by mammography, FNA cytology and/or clinical examination (see Fig.1). The age range of patients was 20 to 81 years (mean  $\pm$  SD,  $52 \pm 14$ ). Where mastectomy for invasive carcinoma was performed, control specimens of macroscopically uninvolved breast tissue (which was later confirmed histologically) were obtained in the same patient (n=27).

### ***Specimen collection***

A previous study of MRS analysis on FNB of thyroid had established that as few as  $10^6$  cells were required to obtain one-dimensional MR spectroscopic data with adequate signal-to-noise in less than 15 minutes (256 accumulations).<sup>16</sup> To achieve an adequate breast sample, FNB was performed using multiple (typically 6) aspirated passes (23 gauge needle) either through the resected lesion *ex vivo* (n=129) or *in vivo* (n=89) after lesion identification during open biopsy. These techniques could be guaranteed to provide cells from the lesion and in addition, allowed the aspiration site to be identified at excision. Tissue from the aspiration site ( $3\text{mm}^3$ ) was collected for correlative histopathology.

### ***Specimen handling***

Cells or tissue were placed in polypropylene vials containing 300  $\mu\text{l}$  phosphate buffered saline (PBS) in  $\text{D}_2\text{O}$ . All specimens were immediately

immersed in liquid nitrogen and stored at  $-70^{\circ}\text{C}$  for up to 6 weeks until MRS analysis.

### ***Preparation of specimens for proton MRS***

Prior to the  $^1\text{H}$  MRS experiment, each FNB specimen was thawed and transferred directly to a 5 mm MRS tube. The volume was adjusted to 300  $\mu\text{l}$  with PBS/D<sub>2</sub>O where necessary. The sample tube was fitted with a capillary insert containing 60  $\mu\text{l}$  para-aminobenzoic acid (10 mM in PBS/D<sub>2</sub>O) as an external standard.

### ***Proton magnetic resonance spectroscopy***

$^1\text{H}$  MRS assessment of all specimens was performed without knowledge of the final histological diagnosis.

**Data acquisition:** MRS experiments were carried out on a Bruker AM-360 wide-bore spectrometer (operating at 360 MHz or 8.5 Tesla) equipped with an Aspect 3000 computer and a standard 5 mm dedicated proton probehead. The sample was spinning at 20 Hz and the temperature maintained at  $37^{\circ}\text{C}$ . Residual water signal was suppressed by selective gated irradiation using low power (15 dB below 0.2 W). The chemical shifts of resonances were referenced to aqueous sodium 3-(trimethylsilyl)-propanesulphonate (TSPS) at 0.00 ppm. One-dimensional spectra were acquired as previously described<sup>18</sup> over a sweep width of 3597 Hz (10.0 ppm) using a ninety degree pulse, 8192 data points, 256 accumulations, an acquisition time of 1.14 seconds and a relaxation delay of 2.00 seconds, resulting in a pulse repetition time of 3.14 seconds.

**Data processing:** Data processing for each specimen was undertaken independently by two operators without access to the histopathology reports, one using the spectrometer's Aspect 3000 computer and the other using a Bruker X32 (UNIX) data station. A line broadening of 3.0 Hz was applied to the data prior to Fourier transformation. Data were phase corrected using zero and first order phase correction. Baselines were corrected using a fourth order polynomial baseline correction routine.



**Data analysis:** The ratio of the peak height intensities of spectral resonances at 3.25 and 3.05 ppm ("MRS Ratio") was calculated by each operator and the two results for each specimen averaged. This ratio was used to generate Figure 3. Data was rejected for inadequate signal to noise (n=11) if the peak intensity of the methylene (-CH<sub>2</sub>-) resonance at 1.3 ppm in the FNB spectrum was less than 40% of the intensities of those generated by the external standard or if the ratio of the -CH<sub>2</sub>- signal intensity to noise intensity was less than 25.

### **Histopathology**

The diagnostic correlation was obtained by comparing the MRS Ratio with the post-operative hospital pathology report provided for each patient. The final histological diagnoses in the study group are shown in Table 1.

Without reference to clinical or MRS data, cytological analysis of the aspirate after MRS analysis was attempted. However, cellular detail was compromised by autolytic changes and this approach was not pursued. In order, therefore, to verify FNB sampling accuracy, separate histopathological assessment by a single pathologist (PR) was obtained from tissue removed from the aspiration site of the MRS sample (see *Specimen Collection*). These tissue specimens were thawed, fixed in FAA (formalin/acetic acid/alcohol), paraffin embedded, sectioned at 7 µm, stained with haematoxylin and eosin according to standard protocols and reviewed by the pathologist under the light microscope without access to the clinical or MRS data. Tissue preservation, abundance of epithelial cells relative to stroma and presence of potentially confounding factors such as fat and inflammatory cells were reported in addition to the principal diagnosis.

### **Other clinical correlations**

Comparisons were made to other pre-operative diagnostic investigations including physical examination, mammography and FNA cytology (separate specimen to MRS).

## RESULTS

### ***Sample collection***

Fine needle aspiration successfully overcame the problem of high levels of MR measurable fat inherent in the analysis of solid breast tissue. The resultant improvement in spectral resolution due to reduction of exogenous fat was confirmed by histopathological analysis (data not shown).

For 207 of the 218 FNB specimens obtained, sufficient cellular material was collected for adequate MR assessment under the chosen experimental conditions. Eleven were discarded for technical reasons (see Methods, *Data analysis*).

### ***Benign lesions versus invasive carcinoma***

Invasive carcinoma was identified by resonances at 3.25 ppm attributable to choline-containing metabolites (Figure 2). A discrimination between invasive carcinoma (n=82) and normal or benign tissue (n=106) was made based on the intensity of the 3.25 ppm resonance standardised to the resonance intensity at 3.05 ppm containing contributions from creatine, phosphocreatine and lysine ( $p < 0.0001$ , Mann-Whitney U test) (see Figure 3). A receiver operating characteristic (ROC) curve using this intensity ratio is shown in Figure 4.

Of 106 benign samples, 102 gave a 3.25/3.05 ppm intensity ratio of less than 1.7. Four false positive results were obtained from 3 palpable fibroadenomas, none of which had FNA cytology performed, and 1 lesion comprising moderate ductal hyperplasia. The diagnoses were based on correlative histopathology.

FNB from 4 of 82 carcinoma had a ratio of  $< 1.7$ . Correlative histopathology from the aspiration site showed that one sample had only benign fibrocystic changes in this region. The other three samples were confirmed as invasive carcinoma but with a marked inflammatory cell infiltrate.

Two cases of Phylloides tumour were studied. One was multifocal and gave a ratio  $> 1.7$ , and the second specimen from a single mass gave a ratio of 1.6. Phylloides tumours are classified as a fibroepithelial proliferation with variable biological activity. Their behaviour ranges from benign through a propensity to local

recurrence to blood-borne metastasis. Both phylloides tumours were excluded from all statistical analysis.

### ***Carcinoma in-situ***

All samples reported as ductal carcinoma-*in-situ* (DCIS) by routine hospital histopathology are shown in Figure 5. These were grouped according to the correlative histopathology findings. No *in-situ* disease was detected in the correlative histopathology of the 6 samples denoted 'benign'. Ductal cells had breached the basement membrane ( $< 1\text{mm}$ ) in one or more focus of the entire DCIS specimen in the 4 samples denoted 'microinvasion'. This group as well as 2 samples of high grade DCIS with extensive comedonecrosis gave ratios  $> 1.7$ . Samples containing only DCIS (10 high grade, 1 low grade) all gave ratios  $\leq 1.7$  indicative of a low choline to creatine/lysine ratio similar to that obtained for benign lesions.

### ***Clinical Correlations***

All cases presenting as mammographically suspicious (n=56), mammographically negative (n=23), or non-diagnostic (n=14) or atypical/suspicious (n=25) FNA cytology, were accurately categorised by MRS (as benign or malignant) as confirmed by histopathology on tissue excised from the aspiration site.

MRS on FNB correlated 96% with the final histological diagnosis of benign lesions (Table 2) and yet, biopsy was performed because of clinical (34%) and/or mammographic features (45%) and/or FNA cytology (31%). MRS on FNB correlated with a malignant histological diagnosis in 95% of cases (Table 2). While combined triple assessment indicated biopsy for all the malignant cases studied, no single pre-operative modality was an improvement on MRS in identifying malignancy (physical examination 84%, mammography 82%, FNA cytology 92%).

## DISCUSSION

MRS on FNB when compared with the histopathological diagnosis has a sensitivity and specificity for the differentiation of invasive carcinoma from benign breast lesions of 95% and 96% respectively, based on the 1D peak intensity ratio of 3.25/3.05 ppm. The increase in ratio observed for carcinoma tissues is most likely due to elevated choline metabolite levels in malignant compared to benign tissues. This is consistent with a higher rate of cellular replication, specifically with increased phospholipid synthesis and membrane turnover.

While triple assessment followed by open biopsy has an overall sensitivity approaching 100%, this entails a high number of open biopsies for benign disease. This is especially the case when equivocal or suspicious mammographic findings are followed by either atypical or suspicious FNA cytology or benign cytology which is incongruous with clinical or radiological findings. In our study, all atypical or suspicious FNA cytology results on subsequently confirmed benign specimens gave a 'benign' MRS ratio on FNB. While the MRS was based on an *ex vivo* aspirate, MRS performed prior to cytology on *in vivo* aspirates may well be a valuable adjunct by improving its specificity. Therefore MRS on FNB could reduce the number of biopsies performed on 'benign' lesions and lead to a more conservative approach such as continued observation/surveillance with repeat FNA cytology and MRS. Used as a complementary modality to triple assessment, MRS on FNB may also provide further diagnostic confidence where open biopsy is requested for patient reassurance only.

MRS on FNB clearly distinguished pure DCIS without comedonecrosis or microinvasion (MRS ratio  $\leq 1.7$ ) from invasive carcinoma. However, even when DCIS specimens contained comedonecrosis or a few foci of microinvasion, MRS ranked the specimen in the invasive category in every case. This may demonstrate the selective sampling of necrotic cells or invasive disease by the MRS FNB, but could also indicate chemical changes occurring in cells progressing from *in-situ* to frankly invasive prior to morphological manifestation. Pure DCIS was not distinguished from benign lesions based on the 1D 3.25/3.05 ppm ratio but more spectral information is available for comparison of the two groups and this is being

investigated. In particular, two-dimensional MRS may identify specific chemical differences characteristic of pure DCIS. Alternatively, multivariate analysis as previously reported for thyroid neoplasms<sup>22</sup>, yet to be undertaken, is likely to improve sensitivity and specificity.

Seventy eight out of 82 invasive carcinoma had an MRS ratio of greater than 1.7. Of the 4 false negative specimens, one was found not to have invasive carcinoma present in the sample which was aspirated. The remaining three samples all had a marked inflammatory infiltrate which, if sampled, may have accounted for a ratio of  $<1.7$ . For all remaining carcinoma specimens, including those which were mammographically negative or non-diagnostic on FNA cytology, MRS correctly indicated malignancy.

In this study, FNB for MRS was collected intra operatively from the exposed lesion to ensure accurate sampling. If MRS on FNB were to be used as a pre-operative diagnostic modality, a sampling error may be introduced similar to that experienced by FNA cytology reducing the sensitivity and specificity recorded here. For example, in this patient sample, 14 out of 143 cytology reports were non-diagnostic or insufficient. Further studies will directly compare MRS with cytology obtained on the same aspirate at the time of clinical assessment.

The potential clinical use of MRS on FNB is to complement triple assessment procedures thus reducing unnecessary biopsy of benign lesions. Management of patients with breast lesions varies, however, from country to country. In Australia FNB is routinely used as part of the triple assessment, thus introducing MRS as a fourth modality would not alter patient management. In the USA, core biopsy is more often employed. Core biopsies have two potential areas of usefulness, viz. demonstrating an invasive focus within an area of DCIS; histological confirmation of radiologically suspected benign lesions. It is anticipated that MRS on FNB will be able to address both these questions as or more accurately than core biopsy, avoiding the more invasive procedure. A core biopsy potentially contains high levels of fat making it unsuitable for MRS analysis. Thus, in countries such as the USA the choice of biopsy procedure will need to be reassessed and re-introduction of FNB measured against the improved sensitivity and specificity of the MRS

method.

Furthermore, it is likely that the technical obstacles to *in vivo* spectroscopy of the breast be overcome. It has been shown in at least one USA site that the diagnostic chemical information reported herein is available *in vivo*. Considerable research and development is required, however, before such techniques will be in routine clinical use.

MRS on *ex vivo* FNB may a) complement 'triple assessment' and reduce the need for unnecessary biopsy of benign lesions and b) obviate the need for open biopsy prior to definitive therapy of invasive lesions by increasing diagnostic specificity of cytology. Pre-operative diagnosis of breast lesions by proton MRS thereby offers potential benefits in patient management by reducing potential morbidity related to biopsy and allaying anxiety due to equivocal diagnosis.

## **ACKNOWLEDGMENTS**

This project was funded by the Australian NH&MRC Grant 950215 and we thank:

The Sydney Breast Cancer Institute, Royal Prince Alfred Hospital; the Hanson Centre, Institute of Medical and Veterinary Science, Adelaide, South Australia for its assistance with sample handling; Professor M. Tattersall for his assistance and guidance with preparation of this manuscript.



## References

1. Tabar L, Fagerberg PG, Duffy SW, Day NE, Gad A, Grontoff O. Update of the swedish two-county program of mammographic screening for breast cancer. *Radiologic Clinics of North America*. 1992; 30: 187-210.
2. Shapiro S, Venet W, Strax P, et al: Ten - to - 14-year effect of screening on breast cancer mortality. *J Natl Canc Inst*. 1982; 69: 349-355.
3. National Program for the Early Detection of Breast Cancer. Monitoring and Evaluation Reference Group. National Program for the early Detection of Breast Cancer - Evaluation of phase one: 1 July 1991 - 30 June 1994., Commonwealth Department of Human Services and Health, Canberra, Australia. December 1994.
4. Dodd GD, Present status of thermography, ultrasound and mammography in breast cancer detection. *Cancer* . 1977; 39: 2796-805.
5. Mahony L, Csimas A. Use and abuse of mammography in the early diagnosis of breast cancer. *Can .J .Surg* .1983; 26: 262-5.
6. Walker QJ, Gebiski V, Langlands AO. The misuse of mammography in the management of breast cancer revisited. *Med .J .Aust* . 1989; 151: 509-12.
7. Niloff PH, Sheiner NH. False-negative mammograms in patients with breast cancer. *Can. J. Surg*. 1981; 24: 50-52.
8. Hiller G, Harney M, Legg, Hart SA. Fine needle aspiration cytology in breast disease management: A four year experience. *Aust N.Z. J. Surg*. 1987; 57: 239-42.
9. Ingram DM, Sterrett GF, Sheiner HJ, Shilkin KB. Fine needle aspiration cytology in the management of breast disease. *Med. J. Aust*. 1983; 2: 170-3.
10. Hermansen C, Poulsen HS, Jensen J et al. Diagnostic reliability of combined physical examination, mammography and fine-needle puncture ("triple-test") in breast tumors. *Cancer*; 1987; 60: 1866-71.
11. Mountford CE, Lean C, Mackinnon WB & Russell P. The use of proton MR in cancer pathology, in: *Annual Reports on NMR Spectroscopy*, (ed.) G.A. Webb, Academic Press, 1993; 27: 173-215.
12. Delikatny EJ, Russell P, Hunter JC, Hancock R, Atkinson K, van Haaften-

- Day C & Mountford CE. Proton MR and human cervical neoplasia. I. *Ex vivo* spectroscopy allows distinction of invasive carcinoma of the cervix from carcinoma *in situ* and other preinvasive lesions. *Radiology* 1993; 188: 791-796.
13. Russell P, Lean CL, Delbridge L, May G, Dowd S & Mountford CE. Proton magnetic resonance and human thyroid neoplasia: I: Discrimination between benign and malignant follicular thyroid neoplasms by magnetic resonance spectroscopy. *Am. J. Med.* 1994; 96: 383-388.
  14. Ende DA, Lean CL, Mackinnon WB, Chapuis P, Newland R, Russell P, Bokey EL & Mountford CE. Human colorectal adenoma-carcinoma sequence documented by  $^1\text{H}$  MRS (*ex vivo*). *Proc. Soc. Magn. Reson. Med.* 1993; 2: 1033.
  15. Mackinnon WB, Russell P, May GL & Mountford CE. Characterisation of human ovarian epithelial tumours (*ex vivo*) by proton magnetic resonance spectroscopy. *Int. J. Gynaecol. Cancer* 1995; 5: 211-221.
  16. Lean CL, Delbridge L, Russell P, May GL, Mackinnon WB, Roman S, Fahey III TJ, Dowd S and Mountford CE. Diagnosis of benign follicular thyroid lesions by proton magnetic resonance on fine needle biopsy. *J. Clin. Endocrinology & Metabolism* 1995; 80: 1306-1311.
  17. Delbridge L, Lean CL, Russell P et al. Proton magnetic resonance and human thyroid neoplasia II: Potential avoidance of surgery for benign follicular neoplasms. *World J. Surg.* 1994; 18: 512-517.
  18. Roman S. A  $^1\text{H}$  MRS study of breast cancer. BSc Med. Thesis, University of Sydney, 1992.
  19. Williams P, Saunders JK, Dyne M, Mountford CE & Holmes KT. Application of a  $T_2$ -filtered COSY experiment to identify the origin of slowly relaxing species in normal and malignant tissue. *Magn. Reson. Med.* 1988; 7: 463-471.
  20. Delikatny EJ, Hull WE & Mountford CE. The effect of altering time domains and window functions in two-dimensional proton COSY spectra of biological specimens. *J. Magn. Res.* 1991; 94: 563-573.

21. Lean CL, Delbridge L, Russell P, May GL & Mountford CE. Proton MRS assessment of fine needle biopsies from thyroid neoplasms. *Proc. Soc. Magn. Reson.* 1994; 2: 78.
22. Somorjai RL, Nikulin AE, Pizzi N et al. Computerized consensus diagnosis: a classification strategy for the robust analysis of mr spectra. I. Application to  $^1\text{H}$  spectra of thyroid neoplasms. *Magn. Reson. Med.* 1995; 33: 257-263.

## FIGURE LEGENDS

**FIGURE 1** Flow chart indicating the management and final histopathological diagnosis of patients involved in the study. The total number of patients sampled was 191. Numbers in parentheses indicate the number of patients who had an uncertain cytological diagnosis during the diagnostic work-up. Numbers alongside arrows indicate the total number of patients. Samples from eleven patients were rejected.

<sup>1</sup> includes invasive and *in-situ* carcinoma.

<sup>2</sup> includes lumpectomy and quadrantectomy. Nine of these patients required a completion mastectomy (not shown).

<sup>3</sup> 12 for *in-situ* carcinoma, 27 for invasive carcinoma

**FIGURE 2** One dimensional <sup>1</sup>H MRS (256 scans) on FNB taken from the same patient. **(A)** Normal uninvolved breast **(B)** Invasive ductal carcinoma. The distinction between normal breast and invasive carcinoma is based on an increase in the N-trimethyl resonance at 3.25 ppm normalised to that of creatine at 3.05 ppm (peaks indicated by arrows). Data was collected as described in **METHODS**.

**FIGURE 3** Plot of the ratio of the intensity of resonances at 3.25 and 3.05 ppm measured from MR spectra as shown in Fig. 2 and as described in materials and methods. Unequivocally benign and invasive lesions are compared. Data are grouped on the basis of the final histopathology of tissue specimens taken from the aspiration site.

**FIGURE 4** Relative Operating Characteristic curve of the data from Fig. 3 (total n = 188) calculated from the 'MRS Ratio' of all samples. The ratio was ranked and both the sensitivity and specificity were calculated for all values of the ratio.

**FIGURE 5** Plot of the ratio of the intensity of resonances at 3.25 and 3.05 ppm measured from samples reported as ductal carcinoma-*in-situ* on post-operative pathology. Data are grouped on the basis of the final correlative histopathology.

**TABLE 1: Summary of Histological Subtypes of FNB samples.**

<b>Benign</b>	
Fibrocystic Changes	68
Fibroadenoma	15
Ductal Hyperplasia (mild / florid)	9
Fat Necrosis	4
Sclerosing Adenosis	2
Radial Scar	2
Atypical Ductal Hyperplasia	2
Duct Ectasia	2
Miscellaneous	2
<b>TOTAL</b>	<b>106</b>
Phyllodes Tumour	2
<b>Ductal Carcinoma <i>in-situ</i></b>	
DCIS - high grade	10
DCIS - low grade	1
DCIS - comedonecrosis	2
DCIS + microinvasion	4
<b>TOTAL</b>	<b>17</b>
<b>Invasive Carcinoma</b>	
Ductal Carcinoma - No Special Type	66
Ductal Carcinoma (NST), EIC positive	7
Lobular Carcinoma	5
Tubular Carcinoma	4
<b>TOTAL</b>	<b>82</b>

DCIS = Ductal Carcinoma *in situ*, NST = No Special Type, EIC = Extensive Intraductal Component. Histopathology according to dominant findings on correlative histopathology samples.

**TABLE 2: TEST RESULT PROBABILITIES FOR DIAGNOSIS BY MRS ON FNB COMPARED WITH HISTOLOGICAL DIAGNOSIS ON TISSUE.**

	Invasive Carcinoma	Normal/Benign	
<b>MRS (FNB) Positive</b>	78	4	PPV 95%
Ratio $\geq 1.7$	(TP)	(FP)	(78/82)
<b>MRS (FNB) Negative</b>	4	102	NPV 96%
Ratio $< 1.7$	(FN)	(TN)	(102/106)
	<b>Sensitivity 95%</b>	<b>Specificity 96%</b>	<b>Total=188</b>
	(78/82)	(102/106)	

TP = True positive; FN = False negative; FP = False positive; TN = True negative; PPV = Positive predictive value; NPV = Negative predictive value; Sensitivity or true-positive rate = frequency of positive test result (ie. MRS ratio  $\geq 1.7$ ) in those with malignant disease; Specificity or true-negative rate = frequency of negative test result (MRS ratio  $< 1.7$ ) in those without malignant disease as judged by histopathology of breast tissue excised from the aspiration site.




Figure 1






Figure 2

# BREAST FNB Benign vs Infiltrating Carcinoma




Figure 3

ROC curve for MRS on FNB




Figure 4




Figure 5